Literature DB >> 24139666

A relic or still relevant: the narrowing role for vagotomy in the treatment of peptic ulcer disease.

Janaka Lagoo1, Theodore N Pappas2, Alexander Perez2.   

Abstract

BACKGROUND: Given the rise of medical treatment for peptic ulcer disease (PUD), surgical treatment is necessary only in select cases and emergencies. The authors assess the current relevance of surgical vagotomy to treat PUD and its complications. DATA SOURCES: Although historically significant, selective and highly selective vagotomy is very technically challenging, and highly selective vagotomy has a relatively narrow indication and high recurrence rates. Vagotomy and gastrectomy is associated with significant side effects. Two types of vagotomy remain relevant, within a narrow scope. Truncal vagotomy and pyloroplasty is safe and efficacious through a laparoscopic approach in certain emergent cases. Vagotomy and Roux-en-Y gastrojejunostomy can be used to treat severe PUD refractory to medical management.
CONCLUSIONS: The role of vagotomy in the management of PUD has a rich history but predated pharmacologic control of acid and understanding of the role of Helicobacter pylori in the disease. Thus, the current role of vagotomy is significantly limited. Specifically, the emergent use of truncal vagotomy is warranted for patients who are either resistant or allergic to proton pump inhibitors.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Highly selective vagotomy; Peptic ulcer disease; Proton pump inhibitors; Selective vagotomy; Truncal vagotomy; Vagotomy

Mesh:

Substances:

Year:  2013        PMID: 24139666     DOI: 10.1016/j.amjsurg.2013.02.012

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   2.565


  17 in total

1.  Decline of open surgical experience for general surgery residents.

Authors:  Katherine Bingmer; Asya Ofshteyn; Sharon L Stein; Jeffrey M Marks; Emily Steinhagen
Journal:  Surg Endosc       Date:  2019-06-10       Impact factor: 4.584

Review 2.  Finding intestinal fortitude: Integrating the microbiome into a holistic view of depression mechanisms, treatment, and resilience.

Authors:  M C Flux; Christopher A Lowry
Journal:  Neurobiol Dis       Date:  2019-08-24       Impact factor: 5.996

3.  Short- and long-term outcomes of surgical management of peptic ulcer complications in the era of proton pump inhibitors.

Authors:  Rabea Hasadia; Yael Kopelman; Oded Olsha; Ricardo Alfici; Itamar Ashkenazi
Journal:  Eur J Trauma Emerg Surg       Date:  2018-01-22       Impact factor: 3.693

Review 4.  Impact of gastric and bowel surgery on gastrointestinal drug delivery.

Authors:  Susan Hua; Ephraem C Lye
Journal:  Drug Deliv Transl Res       Date:  2022-05-18       Impact factor: 4.617

5.  Association of Vagotomy and Decreased Risk of Subsequent Ischemic Stroke in Complicated Peptic Ulcer Patients: an Asian Population Study.

Authors:  Chu-Wen Fang; Chun-Hung Tseng; Shih-Chi Wu; William Tzu-Liang Chen; Chih-Hsin Muo
Journal:  World J Surg       Date:  2017-12       Impact factor: 3.352

Review 6.  Surgery for Peptic Ulcer Disease in sub-Saharan Africa: Systematic Review of Published Data.

Authors:  Jennifer Rickard
Journal:  J Gastrointest Surg       Date:  2015-11-16       Impact factor: 3.452

7.  Effect of Vagus Nerve Integrity on Short and Long-Term Efficacy of Antireflux Surgery.

Authors:  S van Rijn; N F Rinsma; M Y A van Herwaarden-Lindeboom; J Ringers; H G Gooszen; P J J van Rijn; R A Veenendaal; J M Conchillo; N D Bouvy; Adrian A M Masclee
Journal:  Am J Gastroenterol       Date:  2016-03-15       Impact factor: 10.864

Review 8.  Medical versus surgical treatment for refractory or recurrent peptic ulcer.

Authors:  Kurinchi Selvan Gurusamy; Elena Pallari
Journal:  Cochrane Database Syst Rev       Date:  2016-03-29

9.  Priming the (proton) pump.

Authors:  Jonathan D Kaunitz
Journal:  Dig Dis Sci       Date:  2014-07       Impact factor: 3.199

Review 10.  The gut microbiota and gastrointestinal surgery.

Authors:  Kristina Guyton; John C Alverdy
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-10-12       Impact factor: 46.802

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.